Impact of recommended weight-based dosing of granulocyte-colony stimulating factors in acute leukemia and stem cell transplant patients

[1] Kuderer NM(2006)Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients Cancer 106 2258-2266

[2] Dale DC(2010)Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? Support Care Cancer 18 529-541

[3] Crawford J(2007)Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review J Clin Oncol 25 3158-3167

[4] Cosler LE(2015)Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update J Clin Oncol 33 3199-3212

[5] Lyman GH(1994)Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial Ann Intern Med 121 492-501

[6] Aapro M(1994)Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children Pediatr Infect Dis J 13 197-202

[7] Crawford J(1997)A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The international acute myeloid leukemia study group Blood 90 4710-4718

[8] Kamioner D(2008)Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide Am J Health Syst Pharm 65 1552-1555

[9] Kuderer NM(2016)Impact of obesity in favorable-risk AML patients receiving intensive chemotherapy Am J Hematol 91 193-198

[10] Dale DC(1989)Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy J Clin Oncol 7 1554-1562

[1] Kuderer NM(2006)Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients Cancer 106 2258-2266

[2] Dale DC(2010)Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? Support Care Cancer 18 529-541

[3] Crawford J(2007)Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review J Clin Oncol 25 3158-3167

[4] Cosler LE(2015)Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update J Clin Oncol 33 3199-3212

[5] Lyman GH(1994)Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial Ann Intern Med 121 492-501

[6] Aapro M(1994)Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children Pediatr Infect Dis J 13 197-202

[7] Crawford J(1997)A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The international acute myeloid leukemia study group Blood 90 4710-4718

[8] Kamioner D(2008)Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide Am J Health Syst Pharm 65 1552-1555

[9] Kuderer NM(2016)Impact of obesity in favorable-risk AML patients receiving intensive chemotherapy Am J Hematol 91 193-198

[10] Dale DC(1989)Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy J Clin Oncol 7 1554-1562